S
Shruthi Prasad
Researcher at University of Freiburg
Publications - 10
Citations - 345
Shruthi Prasad is an academic researcher from University of Freiburg. The author has contributed to research in topics: T cell & CD8. The author has an hindex of 5, co-authored 9 publications receiving 253 citations.
Papers
More filters
Journal ArticleDOI
Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57
TL;DR: It is found that CD57 was upregulated on activated T cells only upon contact with CD57+ patient-derived GBM-SCs, but not with conventional CD57-negative glioma lines, indicating that this molecule is not a bona fide CSC marker for GBM.
Journal ArticleDOI
Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells
Simone Gaedicke,Friederike Braun,Shruthi Prasad,Marcia Machein,Elke Firat,Michael Hettich,Ravindra Gudihal,Xuekai Zhu,Kerstin Klingner,Julia Schüler,Christel Herold-Mende,Anca-Ligia Grosu,Martin Béhé,Wolfgang A. Weber,Wolfgang A. Weber,Helmut Mäcke,Gabriele Niedermann +16 more
TL;DR: Development of clinically relevant tracers that permit high-sensitivity and high-resolution monitoring of AC133+ glioblastoma stem cells in both subcutaneous and intracerebral xenograft tumors using positron emission tomography and near-infrared fluorescence imaging, two clinically highly relevant imaging modalities are described.
Journal ArticleDOI
Checkpoint Antibodies but not T Cell–Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation
TL;DR: The study reveals the risk that CD3-engaging bsAbs can induce apoptotic TIL depletion followed by rapid tumor regrowth, reminiscent of tolerance induction by CD3 mAb-mediated T-cell depletion, warranting caution in their use for the treatment of solid tumors.
Journal ArticleDOI
Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T Cells
Shruthi Prasad,Simone Gaedicke,Marcia Machein,Gerhard Mittler,Friederike Braun,Michael Hettich,Elke Firat,Kerstin Klingner,Julia Schüler,Dagmar Wider,Ralph Wäsch,Christel Herold-Mende,Ursula Elsässer-Beile,Gabriele Niedermann +13 more
TL;DR: This novel bsAb prevented the outgrowth of AC133-positive subcutaneous GBM xenografts and exhibited potent activity in prophylactic and treatment models of orthotopic GBM-SC-derived invasive brain tumors.
Journal ArticleDOI
Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies.
Julie Preillon,Julia Cuende,Virginie Rabolli,Lucile Garnero,Marjorie Mercier,Noémie Wald,Angela Pappalardo,Sofie Denies,Diane Jamart,Anne-Catherine Michaux,Romain Pirson,Vincent Pitard,Martine Bagot,Shruthi Prasad,Erica Houthuys,Margreet Brouwer,Reece Marillier,Florence Lambolez,Joao Marchante,Florence Nyawouame,Mathew J. Carter,Véronique Baron-Bodo,Anne Marie-Cardine,Mark S. Cragg,Julie Déchanet-Merville,Gregory Driessens,Catherine Hoofd +26 more
TL;DR: In PBMCs from patients with cancer, as well as in tumor-infiltrating lymphocytes from mice, the higher TIGIT expression in Tregs correlated with strong antibody-dependent killing and preferential depletion of this highly immunosuppressive population, providing strong rationale for therapeutic intervention in hematologic malignancies.